Recent advances in the treatment of chronic liver diseases: focus on MASLD/MASH-related fibrosis

Le résumé fourni par la source

Chronic liver diseases (CLDs) represent a growing global health challenge, driven by the increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), its progressive inflammatory-fibrotic form (metabolic dysfunction-associated steatohepatitis - MASH), as well as viral infections, alcoholic liver disease, and autoimmune and cholestatic disorders. Despite intensive research, effective pharmacological therapies capable of halting or reversing fibrosis progression - particularly in MASH - remain lacking. In recent years, incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and a new generation of metabolic multi-agonists, have gained breakthrough significance. These agents demonstrate potent metabolic, anti-inflammatory, and anti-steatotic effects, as well as potential antifibrotic activity, making them promising candidates for the treatment of various CLD phenotypes, including MASLD/MASH-associated fibrosis. This review synthesizes current knowledge on the mechanisms of action of these drugs, clinical trial outcomes, and their potential application as novel, targeted therapies in CLDs.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.